Study of TQB2102 for HER2-negative breast cancer that has spread
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new drug, TQB2102, for people with HER2-negative breast cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug can shrink tumors or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have HER2-negative breast cancer that has spread to other parts of the body and cannot be cured with surgery or radiation.
- You tried at least one type of chemotherapy for the spread cancer, and it either stopped working or caused side effects you couldn't handle.
- You have a tumor that can be measured on a scan (like a CT or MRI).
- You have not had any other cancer (except for some skin cancers) in the last 5 years.
- You are willing to use birth control during and for 6 months after the study (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new HER2-targeted antibody drug (TQB2102) against standard chemotherapy in people with HER2-low breast cancer that has spread or come back. It aims to see if the new drug works better or is safer than usual chemotherapy.
This trial tests a new drug called TQB2102 combined with standard chemotherapy (TCbHP) as a first treatment before surgery for HER2-positive early breast cancer. The goal is to see if this combination works better than the current standard therapy.
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
This study tests a new drug called TQB3126 for people with breast cancer that has worsened after previous treatments. The goal is to see if the drug is safe, how your body processes it, and if it can help shrink or slow the cancer.
This trial tests an experimental drug called TQB2101 for people with advanced solid tumors that have not responded to standard treatments. The study aims to understand how the body handles the drug and what side effects may occur. It may be an option if your tumor has a specific marker called ROR1.
This trial tests a new drug called TQB2102 against a standard treatment (Kadcyla) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those whose cancer has worsened after previous HER2-targeted therapy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.